Benitec Biopharma Inc
For the period ended Jun 30, 2024. Filed Sep 26, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Sep 26, 2024
BNTC$9.28-6.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
(in thousands)
| Year Ended June 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(21,751) | $(19,562) |
| Adjustments to reconcile net loss to net cash from operating activities: | ||
| Depreciation and amortization | 87 | 136 |
| Amortization of right-of-use assets | 256 | 245 |
| Unrealized loss on investment | 1 | 3 |
| Share-based compensation expense | 830 | 452 |
| Changes in operating assets and liabilities: | ||
| Trade and other receivables | (176) | (50) |
| Prepaid and other assets | 645 | (414) |
| Trade and other payables | 941 | 1,357 |
| Accrued employee benefits | 39 | 73 |
| Lease liability | (275) | (252) |
| Net cash used in operating activities | (19,403) | (18,012) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (179) | (1) |
| Net cash used in investing activities | (179) | (1) |
| Cash flows from financing activities: | ||
| Proceeds from issuance and exercise of common stock, pre-funded warrants, Series 2 warrants, and common warrants | 73,921 | 17,884 |
| Share issue transaction costs | (5,892) | (1,869) |
| Net cash provided by financing activities | 68,029 | 16,015 |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | (8) | 412 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 48,439 | (1,586) |
| Cash, cash equivalents, and restricted cash at beginning of year | 2,490 | 4,076 |
| Cash, cash equivalents, and restricted cash at end of year | $50,929 | $2,490 |
| Reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets: | ||
| Cash and cash equivalents | $50,866 | $2,477 |
| Restricted cash | 63 | 13 |
| Total cash, cash equivalents, and restricted cash | $50,929 | $2,490 |
| Supplemental disclosure of cash flow information | ||
| Deemed dividend | $619 | — |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.